Streetbeat News

Analyst Ratings

EXEL

Oppenheimer analyst Jay Olson maintains an Outperform rating on Exelixis (NASDAQ:EXEL) and raises the price target from $25 to $29.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 12:46 pm

LSPD

JP Morgan analyst Tien-Tsin Huang has maintained an Underweight rating on Lightspeed Commerce (NYSE:LSPD) and lowered the price target from $18 to $17.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 12:46 pm

AWH

Alliance Global Partners analyst Ben Haynor has initiated coverage on Aspira Womens Health (NASDAQ:AWH) with a Buy rating and a price target of $5.6.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 12:46 pm

LC

JP Morgan analyst Reginald Smith maintains an Overweight rating on LendingClub (NYSE:LC) and raises the price target from $10 to $11.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 12:45 pm

VRAR

WestPark Capital analyst Casey Ryan has initiated coverage on Glimpse Group (NASDAQ:VRAR) with a Buy rating and a price target of $8.87.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 12:44 pm

GPN

JP Morgan analyst Tien-Tsin Huang maintains a Neutral rating on Global Payments (NYSE:GPN) and raises the price target from $126 to $143.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 12:43 pm

FLYW

JP Morgan analyst Tien-Tsin Huang has maintained an Overweight rating on Flywire (NASDAQ:FLYW) but lowered the price target from $36 to $35.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2023 | 12:42 pm

SLS

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) announced a positive review of the ongoing Phase 3 REGAL clinical trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) by the Independent Data Monitoring Committee (IDMC). The IDMC recommended that the trial continue without modifications. The interim analysis is expected to occur by late 2023 or early 2024, with enrollment completion anticipated in Q4 2023.

Portfolio Pulse from Happy Mohamed

August 22, 2023 | 12:37 pm

M

Telsey Advisory Group has reiterated its 'Market Perform' rating on Macy's (NYSE:M) and maintained its price target of $16.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 12:37 pm

ESTE

Mizuho analyst Nitin Kumar has reiterated a Neutral rating on Earthstone Energy (NYSE:ESTE) and maintained a $22 price target.

Portfolio Pulse from richadhand@benzinga.com

August 22, 2023 | 12:36 pm